RenovoRx Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
17
- Stock Symbol
-
RNXT
- Share Price
-
$1.04
- (As of Friday Closing)
RenovoRx General Information
Description
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Contact Information
Website
www.renovorx.comCorporate Office
- 2570 West El Camino Real
- Suite 320
- Mountain View, CA 94040
- United States
Corporate Office
- 2570 West El Camino Real
- Suite 320
- Mountain View, CA 94040
- United States
RenovoRx Timeline
RenovoRx Stock Performance
As of 13-Nov-2026, RenovoRx’s stock price is $1.04. Its current market cap is $50.2M with 48.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.04 | $1.16 | $0.70 - $2.59 | $50.2M | 48.3M | 817K | -$0.31 |
RenovoRx Financials Summary
As of 30-Sep-2026, RenovoRx has a trailing 12-month revenue of $2.78M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 61,313 | 20,982 | 21,399 | 21,262 |
| Revenue | 2,776 | 1,123 | 43 | 0 |
| EBITDA | (13,294) | (11,594) | (9,198) | (10,340) |
| Net Income | (13,020) | (11,168) | (8,814) | (10,232) |
| Total Assets | 12,437 | 8,095 | 8,118 | 1,466 |
| Total Debt | 358 | 212 | 278 | 0 |
RenovoRx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
RenovoRx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
RenovoRx Comparisons
Industry
Financing
Details
RenovoRx Competitors (6)
One of RenovoRx’s 6 competitors is Kyntra Bio, a Formerly VC-backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kyntra Bio | Formerly VC-backed | San Francisco, CA | ||||
| FibroGen (China) | Corporate Backed or Acquired | Beijing, China | ||||
| Novocure | Formerly VC-backed | Baar, Switzerland | ||||
| TriSalus Life Sciences | Formerly VC-backed | Westminster, CO | ||||
| Perspective Therapeutics | Formerly VC-backed | Seattle, WA |
RenovoRx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
RenovoRx Patents
RenovoRx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026090212-A1 | Adjustable dual-occlusion catheters | Pending | 21-Oct-2024 | ||
| WO-2025240796-A1 | Methods and apparatuses for delivering an agent through vasa vasorum of a vessel | Pending | 15-May-2024 | ||
| JP-2026098092-A | Method and apparatus for delivering drugs through nutrient vessels | Pending | 11-Nov-2022 | ||
| EP-4615341-A2 | Methods and apparatuses for delivering an agent through the vasa vasorum | Pending | 11-Nov-2022 | ||
| US-20260240759-A1 | Methods and apparatuses for delivering an agent through the vasa vasorum | Pending | 11-Nov-2022 | A61K9/0019 |
RenovoRx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
RenovoRx Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
RenovoRx ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Devices
Subindustry
Rank
Percentile
RenovoRx FAQs
-
When was RenovoRx founded?
RenovoRx was founded in 2009.
-
Where is RenovoRx headquartered?
RenovoRx is headquartered in Mountain View, CA.
-
What is the size of RenovoRx?
RenovoRx has 17 total employees.
-
What industry is RenovoRx in?
RenovoRx’s primary industry is Drug Discovery.
-
Is RenovoRx a private or public company?
RenovoRx is a Public company.
-
What is RenovoRx’s stock symbol?
The ticker symbol for RenovoRx is RNXT.
-
What is the current stock price of RenovoRx?
As of 13-Nov-2026 the stock price of RenovoRx is $1.04.
-
What is the current market cap of RenovoRx?
The current market capitalization of RenovoRx is $50.2M.
-
What is RenovoRx’s current revenue?
The trailing twelve month revenue for RenovoRx is $2.78M.
-
Who are RenovoRx’s competitors?
Kyntra Bio, FibroGen (China), Novocure, TriSalus Life Sciences, and Perspective Therapeutics are some of the 6 competitors of RenovoRx.
-
What is RenovoRx’s annual earnings per share (EPS)?
RenovoRx’s EPS for 12 months was -$0.31.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
